Role of fragile histidine triad protein expression in pathogenesis of malignant pleural mesothelioma

Pathology

Volumn 40, Issue 1, 2008, Pages 42-45

  Tutar, Ediz ^a   Kiyici, Halil ^b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Asbestos; FHIT; Ki 67; Malignant pleural mesothelioma

Indexed keywords

ASBESTOS; FORMALDEHYDE; FRAGILE HISTIDINE TRIAD PROTEIN; KI 67 ANTIGEN; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE;

EID: 36448979151     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701716383     Document Type: Article

References (27)

1. Emri S, Akbulut H, Zorlu F, et al. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer 2001; 33: 109-14.
2. McDonald AD, McDonald J. Malignant mesothelioma in North America. Cancer 1980; 46: 1650-6.
3. Senyigit A, Babayigit C, Gokirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the Southeast of Turkey. Respiration 2000; 67: 610-4.
4. Pekarsky Y, Zanesi N, Palamarchuk A, et al. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3: 748-54.
5. Ohta M, Inoue H, Cottecelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-97.
6. Mascaux C, Martin B, Verdebout JM, et al. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53. Eur Respir J 2003; 21: 753-8.
7. Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004; 100: 1605-14.
8. Huang LW, Chao SL, Chen TJ. Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. Gynecol Oncol 2003; 90: 331-7.
9. Fouts RL, Sandusky GE, Zhang S, et al. Down-regulation of fragile histidine triad-expression in prostate carcinoma. Cancer 2003; 97: 1447-52.
10. Baffa R, Gomella LG, Vecchione A, et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 2000; 156: 419-24.
11. Pylkkänen L, Wolff H, Stjernvall T, et al. Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch 2004; 444: 43-8.
12. Cakir C, Gulluoglu MG, Yilmazbayhan D. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology 2006; 38: 10-5.
13. Sington JD, Morris LS, Nicholson AG, et al. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma. Histopathology 2003; 42: 498-502.
14. Kahlos K, Soini Y, Paakko P, et al. Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int J Cancer 2000; 88: 37-43.
15. Lumb PD, Suvarna SK. Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease. Histopathology 2004; 44: 345-52.
16. Otero-Garcia JE, Youssef E, Enamorado II, et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. Am J Otolaryngol 2004; 25: 231-9.
17. Stein CK, Glover TW, Plamer JL, et al. Direct correlation between FRA3B expression and cigarette smoking. Genes Chomosomes Cancer 2002; 34: 333-40.
18. Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771-6.
19. Mineta H, Miura K, Takebayashi S, et al. Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma. Oral Oncol 2002; 39: 56-63.
20. Zimmerman RL. FHIT protein is expressed in benign mesothelium and has no clinical value in detecting carcinoma in body cavity effusions. Appl Immunohistochel Mol Morphol 2000; 8: 154-7.
21. Nelson HH, Wiencke JK, Gunn L, et al. Chromosome 3p14 alterations in lung cancer: Evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998; 58: 1804-7.
22. Comin CE, Anichini C, Boddi V, et al. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 2000; 36: 26-31.
23. Hirano H, Tsuji M, Kizaki T, et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med Electron Microsc 2002; 35: 16-23.
24. Toledo G, Sola JJ, Lozano MD, et al. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol 2004; 17: 440-8.
25. Arun B, Kilic G, Yen C, et al. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 2005; 14: 1681-5.
26. Fischer JR, Ohnmacth U, Rieger N, et al. Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006; 54: 109-16.
27. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618-24.